Carmichael Hill & Associates’s AstraZeneca AZN Stock Holding History

Carmichael Hill & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12	Closed	-$1.55K	–	768
2023 Q4	$1.55K	Hold	12	–	–	﹤0.01%	721
2023 Q3	$1.56K	Hold	12	–	–	﹤0.01%	711
2023 Q2	$1.65K	Hold	12	–	–	﹤0.01%	713
2023 Q1	$1.6K	Hold	12	–	–	﹤0.01%	707
2022 Q4	$1.56K	Sell	12 -50	-81%	-$6.27K	﹤0.01%	703
2022 Q3	$7K	Hold	62	–	–	﹤0.01%	620
2022 Q2	$8K	Hold	62	–	–	﹤0.01%	591
2022 Q1	$8K	Hold	62	–	–	﹤0.01%	626
2021 Q4	$7K	Hold	62	–	–	﹤0.01%	656
2021 Q3	$7K	Buy	62 +12	+24%	+$1.4K	﹤0.01%	640
2021 Q2	$6K	Hold	50	–	–	﹤0.01%	650
2021 Q1	$5K	Sell	50 -25	-33%	-$2.51K	﹤0.01%	647
2020 Q4	$7K	Hold	75	–	–	﹤0.01%	588
2020 Q3	$8K	Hold	75	–	–	0.01%	542
2020 Q2	$8K	Buy	75 +25	+50%	+$2.58K	0.01%	515
2020 Q1	$4K	Hold	50	–	–	﹤0.01%	542
2019 Q4	$5K	Buy	+50	New	+$4.71K	﹤0.01%	547

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Carmichael Hill & Associates's AZN Position: Q1 2024 in Review

Carmichael Hill & Associates sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 12 shares — an estimated $1.55K sold.

Carmichael Hill & Associates first reported a position in AZN in Q4 2019 and held it in 17 quarters. The position peaked at $8K in Q2 2022. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Carmichael Hill & Associates reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
Carmichael Hill & Associates sold 12 AstraZeneca shares in Q1 2024, an estimated $1.55K.
Carmichael Hill & Associates first reported a position in AstraZeneca in Q4 2019 and held it in 17 quarters.
Carmichael Hill & Associates's AstraZeneca position peaked at $8K in Q2 2022.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Carmichael Hill & Associates's 13F filing for Q1 2024, filed 24 Apr 2024.